Hemophilia and other inherited bleeding disorders are rare illnesses. Adverse events related to treatment, such as the development of antibodies to clotting factor concentrate inhibitors, are also rare events. Therefore, it is necessary to follow up with a large number of patients in order to precisely define the relative risk of developing these complications after treatment with the different products.


The European Haemophilia Safety Surveillance system (EUHASS) has been designed to do just this creating a prospective adverse event reporting system for Europe. CHESS is implementing a surveillance scheme in Canada that is compatible with EUHASS and the Canadian Health Registry (CHR)/ Canadian Hemophilia Assessment and Resource Management information System (CHARMS).







IT Development and Support by MDSAS (2013)